The genomic landscape and driver-gene mutations differ significantly among diverse histological subtypes of clear cell renal cell carcinoma (ccRCC) due to the intratumoral heterogeneity. Frequent mutations in canonical DNA damage response genes, such as BRCA1/2 or ATR serine/threonine kinase (ATR) haven't been reported even in large-scale genomic profiling of ccRCC researches. Herein, we reported a rare ccRCC harboring ATR and BRCA2 simultaneous mutation with complicated morphologies and extensive metastases. Our case indicates that the deleterious alteration of DNA damage response genes, increasing CD8+ TILs, high PD1/PD-L1 expression and high TMB might contribute to this patient's tumor metastasis and aggressive biological behavior.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urology.2021.04.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Eur Urol Open Sci
January 2025
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Background And Objective: The role of genetic variants in response to systemic therapy in muscle-invasive bladder cancer (MIBC) is still elusive. We assessed variations in genes involved in DNA damage repair (DDR) before and after cisplatin-based neoadjuvant chemotherapy (NAC) and correlation of alteration patterns with DNA damage and response to therapy.
Methods: Matched tissue from 46 patients with MIBC was investigated via Ion Torrent-based next-generation sequencing using a self-designed panel of 30 DDR genes.
BRCA2 germline mutation carrier with five malignancies: a case report.
Hered Cancer Clin Pract
December 2024
Department of Medical Oncology, Cantonal Hospital Lucerne, Spitalstrasse 16, Lucerne, 6000, Switzerland.
Background: BRCA2 germline mutations are known to predispose carriers to various cancer types, including breast, ovarian, pancreatic and prostate cancer. An association with melanoma has also been reported. However, the full tumour spectrum associated with BRCA2 mutations, particularly in patients with other concurrent pathogenetic mutations, is unexplored.
View Article and Find Full Text PDFATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment.
Br J Cancer
November 2024
IRCM, Univ Montpellier, Inserm, ICM, Montpellier, France.
Article Synopsis
- Pancreatic ductal adenocarcinoma (PDAC) shows treatment resistance due to a dense stroma and immunosuppressive microenvironment, prompting research into combining FOLFIRINOX chemotherapy with VE-822, a DNA repair inhibitor.* -
- The study utilized PDAC spheroid models and mouse models to analyze the combination's effects on tumor growth and the immune and fibrotic environment, revealing a strong synergistic effect and increased apoptosis.* -
- Results indicated that the FOLFIRINOX and VE-822 combo significantly inhibited tumor growth more than FOLFIRINOX alone, improved immune cell activity, and modified the tumor microenvironment, suggesting a potential strategy to enhance treatment effectiveness.*
Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2 ovarian cancer models.
Biochim Biophys Acta Mol Basis Dis
February 2025
Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska Street, 90-236 Lodz, Poland. Electronic address:
Article Synopsis
- Olaparib resistance in ovarian cancer patients calls for new strategies, leading to the creation of a patient-derived xenograft model to study this issue.
- In experiments, olaparib-resistant tumors were treated with olaparib alone, or combined with ATR and CHK1 inhibitors, revealing that these combinations effectively hindered tumor growth and altered key molecular signaling pathways.
- The study enhances our understanding of how to combat olaparib resistance in high-grade serous ovarian cancer with BRCA1/2 mutations, suggesting that targeting the ATR/CHK1 pathways could improve treatment outcomes for patients who are initially unresponsive to olaparib.
Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors.
Cancers (Basel)
October 2024
Department of Chemistry, Division of Food Chemistry and Toxicology, RPTU Kaiserslautern-Landau, 67663 Kaiserslautern, Germany.
The DNA repair protein PARP-1 emerged as a valuable target in the treatment of tumor entities with deficiencies of , such as breast cancer. More recently, the application of PARP inhibitors (PARPi) such as olaparib has been expanded to other cancer entities including colorectal cancer (CRC). We previously demonstrated that PARP-1 is overexpressed in human CRC and promotes CRC progression in a mouse model.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!